Mehdi Razavi is a Cardiology physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6624 Fannin
#2480
Houston, TX 770302309
Telephone
713-529-5530Provider last certified this registry record 28 Mar 2025.
Industry payments
31 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boston Scientific CorporationProgram year20257 payments
- Biosense Webster, Inc.Program year202522 payments
- Abbott LaboratoriesProgram year20258 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
67.8%Antiarrhythmic21.7%Flecainide Acetate43%Propafenone Hcl18%Amiodarone Hcl16%Multaq15%Mexiletine Hcl9%Part D<11 patientsBeta blocker17.7%Metoprolol Succinate61%Metoprolol Tartrate27%Sotalol12%Part D<11 patients+ 7 more classes in this area
Blood & clotting
29.4%Factor Xa inhibitor25.9%Eliquis81%Xarelto19%Part D≥62 patientsVitamin K antagonist1.9%Warfarin Sodium100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
1.5%Potassium supplement1.5%Potassium Chloride100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2019–2026 per NIH RePORTER. The latest:
- Injectable Hydrogel Electrodes to Prevent Ventricular Arrhythmias
University of Texas at Austin
FY2026$549,496R01HL162741 - Injectable Hydrogel Electrodes to Prevent Ventricular Arrhythmias
University of Texas at Austin
FY2025$675,031R01HL162741 - Injectable Hydrogel Electrodes to Prevent Ventricular Arrhythmias
University of Texas at Austin
FY2024$564,151R01HL162741
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”